New treatment and patient selection biomarker for advanced cancer patients

Research

Anti-angiogenic therapy has been demonstrated to increase progression-free survival in patients with many different solid cancers. Unfortunately, the benefit in overall survival is modest and the rapid emergence of drug resistance is a significant clinical problem. There is therefore an urgent need to discover new molecular targets or mechanisms of action for treating resistance to anti-angiogenics, together with new biomarkers to help optimize therapy selection.

Aim

  • To develop a new drug to prevent anti-angiogenics resistance and its companion patient selection biomarker to identify who will benefit from the treatment, thus delivering more efficacious and safer therapies to patients.

Problem to Solve

While targeted therapies have demonstrated efficacy in extending progression-free survival in cancer patients, their benefits are transient and fail to produce durable responses for the majority of patients. In order to fight this resistance, various strategies have been explored. Results obtained from these strategies so far have been modest. This means there is a clear need to develop novel agents that overcome resistance.

Additionally, in the absence of predictive biomarkers, targeted therapies continue to be used in a non-targeted manner. A more personalized approach would allow patients to be specifically matched with the appropriate therapies.

Innovation

The Angiotheragnostics (AtG) team has identified and validated a new therapeutic target to prevent anti-angiogenics resistance, as well as a plasma biomarker that selects patients that will benefit from the treatment. They are now in the early stages of developing this drug and biomarker kit, the first of its kind to target anti-angiogenics resistance.

AtG has identified two families of small molecules that inhibit this target protein, reducing its proliferation in cancer cell lines and impairing tumor growth after anti-angiogenic therapy fails.

Team

Project leader. Group leader, Tumor Angiogenesis Group, ProCURE

Gabriela Jiménez Valerio

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Project leader

Group leader, Tumor Angiogenesis Group, ProCURE

Oriol Casanovas Casanovas

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Head of Medical Oncology and Director of Corporate Research at the Catalan Institute of Oncology

Ramón Salazar Soler

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Head of Innovation Portfolio

Gisela Lorente Marina

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Project Manager de Portafolio de Innovación

Youness Houahid Benkaddour

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

Project Manager de Portafolio de Innovación

Mario de la Cuesta Rivero

IDIBELL - Fundació Institut d’Investigació Biomèdica de Bellvitge

MENTOR

ICREA Research Professor and Co-founder

Roger Gomis

Inbiomotion SL

Partners

Obra social “la Caixa”
Caixa Capital Risc
Validate-19

Scientific Area

Biochemistry and Molecular biology

Business area

Therapeutic

Research center

Instituto de Investigación Biomédica de Bellvitge